歌禮制藥-B(01672.HK)宣佈有望成爲同類最佳的口服小分子IL-17抑制劑ASC50治療銀屑病的美國I期臨牀試驗完成首批受試者給藥
格隆匯6月18日丨歌禮制藥-B(01672.HK)宣佈ASC50在美國進行的隨機、雙盲和安慰劑對照的I期臨牀試驗已完成首批健康受試者給藥,該試驗旨在評估ASC50治療銀屑病的安全性、耐受性和初步療效(NCT07024602)。ASC50爲歌禮自主研發的口服小分子白細胞介素-17(IL-17)靶向抑制劑,IL-17在銀屑病等多種自身免疫及炎症性疾病中已獲充分的生物學驗證並具備成熟商業價值。
ASC50口服片的I期臨牀試驗是一項在美國多箇中心開展的隨機、雙盲、安慰劑對照的首次人體研究,包含健康受試者和輕中度斑塊狀銀屑病人。ASC50口服片由歌禮自主研發。
“我們很高興宣佈ASC50治療銀屑病的臨牀試驗比預期提前完成首批受試者給藥,開啓該候選藥物的臨牀開發。”歌禮制藥創始人、董事會主席兼首席執行官吳勁梓博士表示,“我們期待在不久的將來獲取該研究的頂線數據。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.